UCB
The Global Payer Asset Head leads global access, pricing, reimbursement, and evidence strategies for an innovative cell therapy portfolio, serving as a strategic partner to cross-functional teams and executive leaders. This role drives robust payer strategies to optimize value for patients, healthcare systems, and the company while supporting successful launches and long-term asset growth. The position involves collaborating with internal and external stakeholders to integrate payer perspectives throughout the asset lifecycle.
Headquarters
Brussels, Brussels, Belgium
Company Size
5001-10000 employees
Founded
1928
UCB a global biopharmaceutical leader focuses on creating valuable solutions that improve the lives of people living with neurological and autoimmune conditions
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for UCB.
UCB didn’t post a salary, so this is our estimate from similar listings.
7% below the average for this role
Global Head, Pricing and Market Access Cell Therapy
AstraZeneca
Global Payer Evidence Lead
Novo Nordisk A/S
Global Payer Evidence Lead Obesity
Novo Nordisk A/S
Global Head, Pricing and Market Access Cell Therapy
AstraZeneca
Director, Global Value & Market Access
Alfasigma
Health Economics & Payer Evidence Lead
AstraZeneca